MRK Latest Press Releases

-- December 17, 2025 --

KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery Business Wire 6:45 AM

-- December 12, 2025 --

Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Business Wire 8:45 AM

-- December 9, 2025 --

Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda (Pembrolizumab), in US and Canada PRNewswire 8:52 AM

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada Globe Newswire 7:17 AM

-- December 4, 2025 --

FDA Conditionally Approves Merck Animal Health's EXZOLT CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis) Business Wire 12:05 PM

-- December 2, 2025 --

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now Globe Newswire 8:30 AM

-- December 1, 2025 --

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025 Business Wire 6:45 AM

-- November 26, 2025 --

Merck to Participate in the Citi 2025 Global Healthcare Conference Business Wire 7:15 AM

Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference Business Wire 6:45 AM

-- November 24, 2025 --

Biotech Valuations Rise as New Clinical Platforms Show Progress Globe Newswire 8:30 AM

Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches Business Wire 6:45 AM

-- November 21, 2025 --

Merck Recommends Rejection of Tutanota's "Mini-Tender" Offer Business Wire 7:30 PM

FDA Approves KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Business Wire 4:12 PM

-- November 19, 2025 --

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Nave Adults with HIV-1 Infection Business Wire 6:45 AM

European Commission Approves Subcutaneous Administration of KEYTRUDA (pembrolizumab) for All Adult Indications Approved in the European Union Business Wire 6:30 AM

-- November 18, 2025 --

Merck Announces First-Quarter 2026 Dividend Business Wire 11:31 AM

Merck's WINREVAIR (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF) Business Wire 6:45 AM

-- November 16, 2025 --

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX Business Wire 6:49 PM

-- November 14, 2025 --

Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent Business Wire 6:45 AM

-- November 13, 2025 --

Merck to Participate in the Jefferies Global Healthcare Conference in London Business Wire 6:45 AM

-- November 9, 2025 --

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial Business Wire 5:00 PM

-- November 8, 2025 --

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial Business Wire 2:30 PM

-- November 4, 2025 --

Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT) Business Wire 6:50 AM

Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody Business Wire 6:45 AM

-- November 3, 2025 --

Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S. Business Wire 6:45 AM

-- October 30, 2025 --

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results Business Wire 6:30 AM

-- October 29, 2025 --

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma Business Wire 7:00 AM

European Commission Approves KEYTRUDA (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1) Business Wire 6:45 AM

-- October 28, 2025 --

Merck Announces KEYTRUDA (pembrolizumab) Plus WELIREG (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy Business Wire 6:45 AM

Merck and Eisai Announce WELIREG (belzutifan) Plus LENVIMA (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma Business Wire 6:30 AM

-- October 27, 2025 --

U.S. FDA Approves Updated Indication for WINREVAIR (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study Business Wire 6:45 AM

-- October 23, 2025 --

eschbach's Shiftconnector Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience PRNewswire 11:56 AM

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025 Business Wire 6:45 AM

FDA Grants Priority Review for KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer Business Wire 6:00 AM

-- October 21, 2025 --

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults Business Wire 6:45 AM

-- October 20, 2025 --

KEYTRUDA (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC) Business Wire 8:45 AM

Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia Business Wire 6:45 AM

-- October 19, 2025 --

Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial Business Wire 8:45 AM

-- October 18, 2025 --

KEYTRUDA (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer Business Wire 10:35 AM

KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery Business Wire 10:30 AM

KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire 6:00 AM

-- October 16, 2025 --

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer Business Wire 6:45 AM

-- October 15, 2025 --

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection Business Wire 6:45 AM

-- October 9, 2025 --

Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025 Business Wire 7:00 AM

Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025 Business Wire 6:45 AM

-- October 8, 2025 --

MERCK INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm Globe Newswire 2:59 PM

-- October 7, 2025 --

Merck Completes Acquisition of Verona Pharma Business Wire 6:45 AM

-- October 6, 2025 --

Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases Business Wire 6:45 AM

-- October 1, 2025 --

Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30 Business Wire 6:45 AM

-- September 30, 2025 --

WINREVAIR (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial Business Wire 3:39 AM

-- September 24, 2025 --

Shareholders of Verona Pharma Approve Proposed Acquisition by Merck Globe Newswire 4:05 PM

-- September 19, 2025 --

FDA Approves Merck's KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA (pembrolizumab) Business Wire 5:31 PM

Merck Receives Positive EU CHMP Opinion for ENFLONSIA (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season Business Wire 6:50 AM

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer Business Wire 6:45 AM

-- September 15, 2025 --

Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab Business Wire 7:00 AM

-- September 11, 2025 --

CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease Business Wire 6:45 AM

-- September 7, 2025 --

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial Business Wire 10:45 AM

-- September 2, 2025 --

Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study Business Wire 6:45 AM

Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference Business Wire 6:30 AM

-- September 1, 2025 --

Merck's VICTOR trial did not reach statistical significance for primary endpoint TipRanks 8:39 AM

-- August 30, 2025 --

?? ???, CDC ??? ?? ?? ??? ??? ?? RFK ??? ?? ?? Mohd Haider 10:55 PM

??????????CDC??????????????????????RFK Jr.?????? Mohd Haider 10:55 PM

Bernie Sanders exige la dmission du secrtaire la sant RFK Jr. alors que la crise du leadership au CDC s'aggrave Mohd Haider 10:55 PM

???? ?????? ????? ???????? ???? ????? RFK Jr. ?? ????? ???? ????? ???? ??????? ??? ??????? ???????? ???? Mohd Haider 10:55 PM

Bernie Sanders fordert den Rcktritt von Gesundheitsminister RFK Jr., da sich die Fhrungskrise der CDC vertieft Mohd Haider 10:55 PM

Bernie Sanders chiede le dimissioni del Segretario alla Salute RFK Jr. mentre si approfondisce la crisi di leadership dei CDC Mohd Haider 10:55 PM

????????????????,CDC?????? Mohd Haider 10:55 PM

Bernie Sanders exige la renuncia del Secretario de Salud RFK Jr. a medida que la crisis de liderazgo de los CDC se profundiza Mohd Haider 10:55 PM

Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepens Mohd Haider 10:55 PM

Merck Provides New Results for VERQUVO (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Business Wire 2:45 AM

-- August 28, 2025 --

Merck to Participate in the 2025 Wells Fargo Healthcare Conference Business Wire 6:45 AM

-- August 27, 2025 --

HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy Business Wire 7:00 AM

-- August 25, 2025 --

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025 Business Wire 6:45 AM

-- August 19, 2025 --

Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds Business Wire 6:45 AM

-- August 18, 2025 --

The Next Wave of Cancer Innovation: How Breakthrough Therapies Are Redefining Treatment Paradigms Yolowire 7:40 AM

Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer Business Wire 7:00 AM

-- August 12, 2025 --

KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery Business Wire 5:33 AM

-- August 11, 2025 --

REPAY Appoints New Chief Financial Officer Business Wire 4:06 PM

-- July 29, 2025 --

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results Business Wire 6:30 AM

-- July 22, 2025 --

Merck Announces Fourth-Quarter 2025 Dividend Business Wire 11:53 AM

-- July 21, 2025 --

Merck Commits to Veeva Vault CRM PRNewswire 10:00 AM

-- July 19, 2025 --

MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm Globe Newswire 2:54 PM